Developer docs
API playgroundTry for free, no card

Search company profiles

Experimental Pathology Laboratorie

Full company profile

uuid000ma3c

Namestring
Experimental Pathology Laboratorie
Legal namestring
Experimental Pathology Laboratories, Inc.
Websiteurl
epl-inc.com
Company typeenum
Private
Founded yearint
1971
Descriptiontext

Experimental Pathology Laboratories, Inc. (EPL) is a US-based preclinical pathology services firm founded in 1971 and employee-owned since 1992. Headquartered in Sterling, Virginia with regional offices in West Lafayette (IN), Collegeville (PA), and Boston (MA), EPL provides histopathology, toxicologic pathology, peer review, Pathology Working Groups, whole slide imaging, design-based stereology, immunohistochemistry, electron microscopy, and SEND-compliant data services to pharmaceutical, biotechnology, chemical, medical device, CRO, academic, and government clients (notably the NCI/NTP program). The company operates through four US regional hubs plus international alliances in Greater China and Taiwan, processing up to 50,000 tissues per month and conducting roughly 180-250 peer reviews annually.

EPL's technical platform combines wet-lab histology capabilities with proprietary software: the PQA pathology peer review system that runs on portable laptops and interfaces study data via ASCII text files; design-based stereology conducted across three anatomical planes for unbiased quantitative measurements; high-throughput whole slide imaging for digital pathology workflows; and validated TranSEND/Ascentos pipelines for SEND-compliant FDA submissions. The subsidiary Aclairo Pharmaceutical Development Group (acquired January 2016) layers nonclinical, regulatory, and ADME/DMPK consulting on top of the pathology core. EPL differentiates from full-service CROs through a 'scale without mass' specialist model — over 100 highly trained staff including board-certified veterinary pathologists, several former presidents of the Society of Toxicologic Pathology, and senior scientists recruited from GlaxoSmithKline, AstraZeneca, Hoffmann-La Roche, and Biogen.

Commercially, EPL is a project-based professional services firm selling customized preclinical pathology engagements on multi-year contract terms via direct business development, conference presence (SOT, STP, ACT, SETAC), and on-site pathologist travel to client laboratories. Pricing is quote-driven and varies by protocol, species, tissue count, regulatory pathway, and turnaround. Revenue is not publicly disclosed; the company has no venture or private equity backing, has never raised outside capital, and operates as an independent employee-owned entity, with growth funded internally through organic hiring and selective alliances rather than M&A or capital markets activity.

Short descriptiontext

Experimental Pathology Laboratories (EPL) is a US-based, employee-owned preclinical pathology services firm founded in 1971, providing histopathology, toxicologic pathology, peer review, and SEND-compliant data services to pharmaceutical, biotech, chemical, medical device, and government clients including the NCI/NTP program.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSterling, United States
HQ citystring
Sterling
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical pathology services, toxicologic pathology evaluation, histopathology peer review, SEND-compliant data services, nonclinical safety assessment
Industry4 codes
PRIMARYHLAGAFAI
Pathology & Histopathology Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAEAC
Anatomic Pathology & Histopathology (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLACAOAN
Regulatory Submissions & Clinical Content Management (eCTD/Publishing)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAMADAB
Veterinary Anatomic Pathology (Histopathology & Cytology)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Diagnostics (Labs & Imaging)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Other Scientific and Technical Consulting Services541690
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Preclinical Pathology Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Professional Pathology Services
TypeProfessional Services
Description

EPL generates revenue through project-based professional services contracts for histopathology, toxicologic pathology evaluation, pathology peer review, Pathology Working Groups, consulting, and specialized laboratory services including stereology, immunohistochemistry, and electron microscopy. Services are provided to pharmaceutical, biotechnology, chemical companies, government agencies, and academia on a per-project basis.

epl-inc.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Project-based professional pathology services - pricing varies by scope, complexity, and turnaround requirements
ModelOtherBilling cadenceMulti-year contract
Notes

Services are provided on a per-project basis with quotes generated based on protocol requirements, species, number of animals, tissue types, regulatory status, and timeline requirements. Expedited scheduling available on a case-by-case basis.

epl-inc.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Experimental Pathology Laboratories, Inc. (EPL) provides preclinical histopathology and toxicologic pathology services on a project basis to pharmaceutical, biotechnology, and chemical companies as well as government agencies and academia. Services span histology (H&E, immunohistochemistry, specialty stains, necropsy), pathology evaluation (carcinogenicity, peer review, Pathology Working Groups, aquatic/avian pathology), digital whole slide imaging and stereology, transmission electron microscopy, SEND-compliant data services, and expert scientific/regulatory consulting.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Processing up to 50,000 tissues per month
+3 more records
Product overview1 text field

Experimental Pathology Laboratories, Inc. (EPL) is a preclinical pathology services company offering a comprehensive portfolio of histopathology and toxicologic pathology services. Founded in 1971 and employee-owned since 1992, the company provides histology services (including routine H&E, immunohistochemistry, and specialty stains), pathology evaluation (carcinogenicity studies, peer review, working groups), imaging services (whole slide scanning, image analysis, stereology), SEND-compliant data services, and toxicology/consulting support. The company also operates Aclairo Pharmaceutical Development Group as a wholly owned subsidiary providing regulatory and nonclinical consulting. EPL leverages proprietary software including the PQA pathology peer review system and validated TranSEND/Ascentos platforms for SEND submissions. Services are delivered through laboratories in Sterling, VA (headquarters), North Carolina, Midwest (West Lafayette, IN), Northeast (Collegeville, PA), and Boston, MA.

Product and service14 records
1Histology Services
CategoryPreclinical Pathology Services
Description

Histology services including aquatic animal and avian histology, immunohistochemistry, necropsy, routine H&E staining, and specialty histochemical stains for pharmaceutical, biotechnology, chemical companies, government agencies, and academia.

2Pathology Services
CategoryPreclinical Pathology Services
Description

Toxicologic pathology evaluation including aquatic and avian pathology, carcinogenicity and chronic studies, organ-based expertise, pathology working groups, peer review, research animal models, and transmission electron microscopy.

3Whole Slide Imaging Services
CategoryDigital Pathology / Imaging
Description

High-throughput whole slide imaging using advanced digital pathology technologies for consultation, peer review, education, and quantitative analysis through high-quality digital slide capture and secure image sharing.

4Image Analysis
CategoryDigital Pathology / Imaging
Description

Image analysis services for quantitative analysis of tissue samples, supporting toxicologic pathology and nonclinical safety studies.

5Stereology Services
6Stereology Services
CategoryDigital Pathology / Imaging
Description

Design-based stereology for unbiased, quantitative measurements of structures within biological tissues, providing more objective and accurate results compared to traditional semi-quantitative grading. EPL has been conducting design-based stereology in industry environments for 10 continuous years.

7SEND Data Services
CategoryRegulatory Data Services
Description

Standard for Exchange of Nonclinical Data (SEND) compliant dataset preparation and submission services using validated Ascentos and TranSEND software, providing FDA-ready datasets for NDA/BLA/ANDA submissions initiated after December 2016 and IND submissions after December 2017.

8Pathology Peer Review
CategoryPreclinical Pathology Services
Description

Third-party pathology peer review using proprietary PQA software to improve quality of pathology data and ensure regulatory compliance, conducted on-site or remotely. Over 250 peer reviews conducted in two years; 189 peer reviews in 2017 alone.

9Pathology Working Groups (PWG)
CategoryPreclinical Pathology Services
Description

Expert pathologist panels convened to answer specific questions and provide independent unbiased opinions regarding study results for regulatory and sponsor needs.

10Consulting Services
CategoryPreclinical Pathology Services
Description

Expert scientific and regulatory consulting for preclinical drug development, nonclinical safety assessment, and regulatory strategy.

11Toxicology Services
CategoryPreclinical Pathology Services
Description

Comprehensive toxicology support services for preclinical safety testing and drug development programs.

12Immunohistochemistry (IHC) Services
CategoryHistology
Description

Immunohistochemistry services for identification and localization of tissue antigens using validated protocols for formalin-fixed paraffin embedded tissues, with digital imaging and image analysis capabilities.

13Transmission Electron Microscopy (TEM)
CategoryPreclinical Pathology Services
Description

Electron microscopy services provided in partnership with Virginia Tech Laboratory for Neurotoxicity Studies, offering GLP-compliant transmission electron microscopy for nonclinical studies through the alliance established August 25, 2014.

14Aclairo Pharmaceutical Development Group
CategoryRegulatory & Nonclinical Consulting
Description

Wholly owned subsidiary providing independent and objective nonclinical and regulatory advice to the pharmaceutical industry, including FDA strategy, due diligence, and product development consulting. Acquired by EPL on January 1, 2016.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-05-07
Description

Strategic alliance announced May 2020 to provide EPL's preclinical pathology expertise as an important resource to QS3. QS3 is a research and consulting company with six principals having over 200 years of combined research experience and more than 1,000 publications. Specialists in mode and mechanisms of action of chemicals, environmental transport, fate, and effects. QS3 principals include Drs. Charles Breckenridge, Ralph Cooper, Bob Handa, Peter Hertl, Tony Plant, and Jim Simpkins.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2017-07-27
Description

Technology partnership for SEND-compliant data solutions. EPL validated the Ascentos pathology information management system and TranSEND software solution by PDS Life Sciences. Through TranSEND software, EPL provides SEND-compliant datasets ready for FDA submission. SEND formats required for studies started after Dec 2016 for NDAs/BLAs/ANDAs and Dec 2017 for INDs.

3WestChina-Frontier PharmaTech Co., Ltd. (WCFP)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-03-28
Description

Strategic alliance to enhance preclinical services. EPL provides Pathology Peer Review Services for WCFP projects being submitted to international regulatory agencies. WCFP, founded in February 2000 in Chengdu, China, is a professional CRO providing GLP safety and efficacy evaluations. WCFP has OECD, CAP, CFDA-GLP, and AAALAC accreditation with 380 staff including CFDA New Drug Reviewers and national-class pathologists.

epl-inc.com
4Expedient Solutions International (ESI) and Dr. Ada H.C. Kung
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-03-10
Description

Strategic alliance with EPL, Aclairo, and ESI to enhance Preclinical Pathology and Regulatory Consulting Services to the Greater China pharmaceutical and biotechnology industry. Initial focus on pathology peer reviews, pathology training, and IND application review for US FDA submissions. Dr. Kung formed ESI in 2008 and has rare combination of China and US drug development expertise, having submitted two of the first INDs to US FDA using data from China labs.

epl-inc.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

EPL acquired Aclairo Pharmaceutical Development Group, Inc. on January 1, 2016. Aclairo is now a wholly owned subsidiary of EPL and provides independent and objective nonclinical, regulatory, and clinical ADME/DMPK expert strategy and implementation to pharmaceutical and drug device industries. Aclairo's team includes industry and ex-FDA experts providing specialized consultancy services. Leadership includes Dr. Hilary Sheevers (President), Dr. Susan Wilson (Vice President), Dr. Robert Guttendorf (Chief Scientific Officer), Dr. Laura Dill Morton (Director of Toxicology), and Dr. Tacey White (Director of Operations).

6Laboratory for Neurotoxicity Studies (LNS) at Virginia-Maryland College of Veterinary Medicine, Virginia Tech
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2014-08-25
Description

Electron microscopy services alliance. LNS is a fully GLP-compliant, state-of-the-art transmission electron microscopy laboratory supporting regulatory studies for over 25 years. Located at Virginia-Maryland College of Veterinary Medicine in Blacksburg, VA. Directed by Dr. Bernard Jortner, a board-certified veterinary pathologist with over 40 years of experience in neuropathology, toxicology, and ultrastructural research.

epl-inc.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2014-07-31
Description

Collaborative research partnership investigating morphologic effects of environmental contaminant hexavalent chromium on small intestines using histopathology, image analysis, and X-ray fluorescence spectromicroscopy. EPL provides pathology expertise and advanced imaging techniques for multidisciplinary research projects.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2014-01-01
Description

Strategic alliance to enhance medical device and biomaterial testing capabilities. Histion is an Everett, Washington-based preclinical laboratory specializing in GLP-compliant routine and specialty histology and evaluation services. Alliance targeted to expand capabilities for medical device and novel biomaterial testing.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Large global CRO offering preclinical toxicology and anatomic pathology services to pharma and biotech; competes directly with EPL for toxicologic pathology, peer review and SEND-related work but as part of a much broader services portfolio.

TypeDirect peer
Description

Preclinical research services and contract research organization providing toxicology, pathology and animal model services; competes with EPL for outsourced toxicologic pathology and safety assessment work.

3Seventh Wave Laboratories
TypeDirect peer
Description

Mid-sized preclinical CRO focused on safety assessment, toxicology and pathology services for emerging biopharma; comparable specialty focus and client base to EPL.

TypeDirect peer
Description

Full-service CRO (formerly Covance) providing preclinical safety, pathology and bioanalytical services; overlaps EPL on toxicologic pathology and SEND data services within an integrated early-development offering.

TypeEmerging player
Description

Scientific consulting firm with capabilities in toxicologic pathology, risk assessment and regulatory strategy; partial overlap with EPL's consulting and pathology peer review offerings.

6Absorption Systems
TypeDirect peer
Description

Preclinical CRO offering toxicology, pathology and ADME services to pharma and biotech; competes with EPL on toxicologic pathology and SEND-enabled safety packages.

TypeDirect peer
Description

Global preclinical and clinical CRO with extensive toxicologic pathology capacity; direct competitor for international pharma sponsors and a natural alternative to EPL's US-China peer review pathway.

TypeBroad incumbent
Description

Broader discovery and preclinical services platform including safety assessment and pathology; overlaps with EPL on toxicologic pathology within a much wider CRO and testing portfolio.

9WestChina-Frontier PharmaTech (WCFP)
TypeRegional player
Description

China-based GLP CRO providing safety and efficacy evaluations; EPL's alliance partner and a regional peer for pathology peer review services tied to FDA-bound China studies.

TypeOthers
Description

Provider of preclinical software including the Ascentos and TranSEND SEND platforms that EPL has validated; adjacent technology enabler rather than direct pathology services competitor.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile6 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Experimental Pathology Laboratorie

Preclinical Pathology Servicesepl-inc.com

Experimental Pathology Laboratories (EPL) is a US-based, employee-owned preclinical pathology services firm founded in 1971, providing histopathology, toxicologic pathology, peer review, and SEND-compliant data services to pharmaceutical, biotech, chemical, medical device, and government clients including the NCI/NTP program.

What Experimental Pathology Laboratorie does

Experimental Pathology Laboratories, Inc. (EPL) is a US-based preclinical pathology services firm founded in 1971 and employee-owned since 1992. Headquartered in Sterling, Virginia with regional offices in West Lafayette (IN), Collegeville (PA), and Boston (MA), EPL provides histopathology, toxicologic pathology, peer review, Pathology Working Groups, whole slide imaging, design-based stereology, immunohistochemistry, electron microscopy, and SEND-compliant data services to pharmaceutical, biotechnology, chemical, medical device, CRO, academic, and government clients (notably the NCI/NTP program). The company operates through four US regional hubs plus international alliances in Greater China and Taiwan, processing up to 50,000 tissues per month and conducting roughly 180-250 peer reviews annually.

EPL's technical platform combines wet-lab histology capabilities with proprietary software: the PQA pathology peer review system that runs on portable laptops and interfaces study data via ASCII text files; design-based stereology conducted across three anatomical planes for unbiased quantitative measurements; high-throughput whole slide imaging for digital pathology workflows; and validated TranSEND/Ascentos pipelines for SEND-compliant FDA submissions. The subsidiary Aclairo Pharmaceutical Development Group (acquired January 2016) layers nonclinical, regulatory, and ADME/DMPK consulting on top of the pathology core. EPL differentiates from full-service CROs through a 'scale without mass' specialist model — over 100 highly trained staff including board-certified veterinary pathologists, several former presidents of the Society of Toxicologic Pathology, and senior scientists recruited from GlaxoSmithKline, AstraZeneca, Hoffmann-La Roche, and Biogen.

Commercially, EPL is a project-based professional services firm selling customized preclinical pathology engagements on multi-year contract terms via direct business development, conference presence (SOT, STP, ACT, SETAC), and on-site pathologist travel to client laboratories. Pricing is quote-driven and varies by protocol, species, tissue count, regulatory pathway, and turnaround. Revenue is not publicly disclosed; the company has no venture or private equity backing, has never raised outside capital, and operates as an independent employee-owned entity, with growth funded internally through organic hiring and selective alliances rather than M&A or capital markets activity.

Experimental Pathology Laboratorie firmographics

Firmographics
Name
Experimental Pathology Laboratorie
Legal name
Experimental Pathology Laboratories, Inc.
Website
https://epl-inc.com
Company type
Private
Founded year
1971
Operating status
Operating
Headcount range
101–250 employees
Short description
Experimental Pathology Laboratories (EPL) is a US-based, employee-owned preclinical pathology services firm founded in 1971, providing histopathology, toxicologic pathology, peer review, and SEND-compliant data services to pharmaceutical, biotech, chemical, medical device, and government clients including the NCI/NTP program.
Ownership category
akta.pro rank

Experimental Pathology Laboratorie industry classification

Industry
Product category
Preclinical Pathology Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (541690)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAFAI
Pathology & Histopathology Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAEAC
Anatomic Pathology & Histopathology (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLACAOAN
Regulatory Submissions & Clinical Content Management (eCTD/Publishing)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAMADAB
Veterinary Anatomic Pathology (Histopathology & Cytology)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Diagnostics (Labs & Imaging)

Keywords

  • Preclinical pathology services
  • Toxicologic pathology evaluation
  • Histopathology peer review
  • SEND-compliant data services
  • Nonclinical safety assessment

Where Experimental Pathology Laboratorie is headquartered

Location

Headquarters

HQ city
Sterling
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Experimental Pathology Laboratorie business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Professional Pathology Services: EPL generates revenue through project-based professional services contracts for histopathology, toxicologic pathology evaluation, pathology peer review, Pathology Working Groups, consulting, and specialized laboratory services including stereology, immunohistochemistry, and electron microscopy. Services are provided to pharmaceutical, biotechnology, chemical companies, government agencies, and academia on a per-project basis.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based professional pathology services - pricing varies by scope, complexity, and turnaround requirements

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Experimental Pathology Laboratorie product offering

Product offering

Core offering

Experimental Pathology Laboratories, Inc. (EPL) provides preclinical histopathology and toxicologic pathology services on a project basis to pharmaceutical, biotechnology, and chemical companies as well as government agencies and academia. Services span histology (H&E, immunohistochemistry, specialty stains, necropsy), pathology evaluation (carcinogenicity, peer review, Pathology Working Groups, aquatic/avian pathology), digital whole slide imaging and stereology, transmission electron microscopy, SEND-compliant data services, and expert scientific/regulatory consulting.

Product overview

Experimental Pathology Laboratories, Inc. (EPL) is a preclinical pathology services company offering a comprehensive portfolio of histopathology and toxicologic pathology services. Founded in 1971 and employee-owned since 1992, the company provides histology services (including routine H&E, immunohistochemistry, and specialty stains), pathology evaluation (carcinogenicity studies, peer review, working groups), imaging services (whole slide scanning, image analysis, stereology), SEND-compliant data services, and toxicology/consulting support. The company also operates Aclairo Pharmaceutical Development Group as a wholly owned subsidiary providing regulatory and nonclinical consulting. EPL leverages proprietary software including the PQA pathology peer review system and validated TranSEND/Ascentos platforms for SEND submissions. Services are delivered through laboratories in Sterling, VA (headquarters), North Carolina, Midwest (West Lafayette, IN), Northeast (Collegeville, PA), and Boston, MA.

Differentiator

Problem solved

Functional benefit

Products and services

  • Histology Services Histology services including aquatic animal and avian histology, immunohistochemistry, necropsy, routine H&E staining, and specialty histochemical stains for pharmaceutical, biotechnology, chemical companies, government agencies, and academia.
  • Pathology Services Toxicologic pathology evaluation including aquatic and avian pathology, carcinogenicity and chronic studies, organ-based expertise, pathology working groups, peer review, research animal models, and transmission electron microscopy.
  • Whole Slide Imaging Services High-throughput whole slide imaging using advanced digital pathology technologies for consultation, peer review, education, and quantitative analysis through high-quality digital slide capture and secure image sharing.
  • Image Analysis Image analysis services for quantitative analysis of tissue samples, supporting toxicologic pathology and nonclinical safety studies.
  • Stereology Services
  • Stereology Services Design-based stereology for unbiased, quantitative measurements of structures within biological tissues, providing more objective and accurate results compared to traditional semi-quantitative grading. EPL has been conducting design-based stereology in industry environments for 10 continuous years.
  • SEND Data Services Standard for Exchange of Nonclinical Data (SEND) compliant dataset preparation and submission services using validated Ascentos and TranSEND software, providing FDA-ready datasets for NDA/BLA/ANDA submissions initiated after December 2016 and IND submissions after December 2017.
  • Pathology Peer Review Third-party pathology peer review using proprietary PQA software to improve quality of pathology data and ensure regulatory compliance, conducted on-site or remotely. Over 250 peer reviews conducted in two years; 189 peer reviews in 2017 alone.
  • Pathology Working Groups (PWG) Expert pathologist panels convened to answer specific questions and provide independent unbiased opinions regarding study results for regulatory and sponsor needs.
  • Consulting Services Expert scientific and regulatory consulting for preclinical drug development, nonclinical safety assessment, and regulatory strategy.
  • Toxicology Services Comprehensive toxicology support services for preclinical safety testing and drug development programs.
  • Immunohistochemistry (IHC) Services Immunohistochemistry services for identification and localization of tissue antigens using validated protocols for formalin-fixed paraffin embedded tissues, with digital imaging and image analysis capabilities.
  • Transmission Electron Microscopy (TEM) Electron microscopy services provided in partnership with Virginia Tech Laboratory for Neurotoxicity Studies, offering GLP-compliant transmission electron microscopy for nonclinical studies through the alliance established August 25, 2014.
  • Aclairo Pharmaceutical Development Group Wholly owned subsidiary providing independent and objective nonclinical and regulatory advice to the pharmaceutical industry, including FDA strategy, due diligence, and product development consulting. Acquired by EPL on January 1, 2016.

Quantifiable outcome

  • Processing up to 50,000 tissues per month
  • +3 more outcomes

Companies that use Experimental Pathology Laboratorie

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles6 records

Experimental Pathology Laboratorie technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Experimental Pathology Laboratorie partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Quality Scientific Solutions, LLC (QS3)coreStrategic or Co-development Partner · 7 May 2020Strategic alliance announced May 2020 to provide EPL's preclinical pathology expertise as an important resource to QS3. QS3 is a research and consulting company with six principals having over 200 years of combined research experience and more than 1,000 publications. Specialists in mode and mechanisms of action of chemicals, environmental transport, fate, and effects. QS3 principals include Drs. Charles Breckenridge, Ralph Cooper, Bob Handa, Peter Hertl, Tony Plant, and Jim Simpkins.
  • PDS Life SciencescoreTechnology or Integration · 27 July 2017Technology partnership for SEND-compliant data solutions. EPL validated the Ascentos pathology information management system and TranSEND software solution by PDS Life Sciences. Through TranSEND software, EPL provides SEND-compliant datasets ready for FDA submission. SEND formats required for studies started after Dec 2016 for NDAs/BLAs/ANDAs and Dec 2017 for INDs.
  • WestChina-Frontier PharmaTech Co., Ltd. (WCFP)coreStrategic or Co-development Partner · 28 March 2017Strategic alliance to enhance preclinical services. EPL provides Pathology Peer Review Services for WCFP projects being submitted to international regulatory agencies. WCFP, founded in February 2000 in Chengdu, China, is a professional CRO providing GLP safety and efficacy evaluations. WCFP has OECD, CAP, CFDA-GLP, and AAALAC accreditation with 380 staff including CFDA New Drug Reviewers and national-class pathologists.
  • Expedient Solutions International (ESI) and Dr. Ada H.C. KungcoreStrategic or Co-development Partner · 10 March 2017Strategic alliance with EPL, Aclairo, and ESI to enhance Preclinical Pathology and Regulatory Consulting Services to the Greater China pharmaceutical and biotechnology industry. Initial focus on pathology peer reviews, pathology training, and IND application review for US FDA submissions. Dr. Kung formed ESI in 2008 and has rare combination of China and US drug development expertise, having submitted two of the first INDs to US FDA using data from China labs.
  • Aclairo Pharmaceutical Development Group, Inc.coreStrategic or Co-development Partner · 1 January 2016EPL acquired Aclairo Pharmaceutical Development Group, Inc. on January 1, 2016. Aclairo is now a wholly owned subsidiary of EPL and provides independent and objective nonclinical, regulatory, and clinical ADME/DMPK expert strategy and implementation to pharmaceutical and drug device industries. Aclairo's team includes industry and ex-FDA experts providing specialized consultancy services. Leadership includes Dr. Hilary Sheevers (President), Dr. Susan Wilson (Vice President), Dr. Robert Guttendorf (Chief Scientific Officer), Dr. Laura Dill Morton (Director of Toxicology), and Dr. Tacey White (Director of Operations).
  • Laboratory for Neurotoxicity Studies (LNS) at Virginia-Maryland College of Veterinary Medicine, Virginia TechcoreTechnology or Integration · 25 August 2014Electron microscopy services alliance. LNS is a fully GLP-compliant, state-of-the-art transmission electron microscopy laboratory supporting regulatory studies for over 25 years. Located at Virginia-Maryland College of Veterinary Medicine in Blacksburg, VA. Directed by Dr. Bernard Jortner, a board-certified veterinary pathologist with over 40 years of experience in neuropathology, toxicology, and ultrastructural research.
  • ToxStrategiesminorStrategic or Co-development Partner · 31 July 2014Collaborative research partnership investigating morphologic effects of environmental contaminant hexavalent chromium on small intestines using histopathology, image analysis, and X-ray fluorescence spectromicroscopy. EPL provides pathology expertise and advanced imaging techniques for multidisciplinary research projects.
  • HistionminorStrategic or Co-development Partner · 1 January 2014Strategic alliance to enhance medical device and biomaterial testing capabilities. Histion is an Everett, Washington-based preclinical laboratory specializing in GLP-compliant routine and specialty histology and evaluation services. Alliance targeted to expand capabilities for medical device and novel biomaterial testing.

Scale indicators7 records

Recent moves9 records

Expansion highlights5 records

Experimental Pathology Laboratorie competitors and assessment

Company assessment

Direct peers

  • Charles River Laboratories: Large global CRO offering preclinical toxicology and anatomic pathology services to pharma and biotech; competes directly with EPL for toxicologic pathology, peer review and SEND-related work but as part of a much broader services portfolio.
  • Inotiv: Preclinical research services and contract research organization providing toxicology, pathology and animal model services; competes with EPL for outsourced toxicologic pathology and safety assessment work.
  • Seventh Wave Laboratories: Mid-sized preclinical CRO focused on safety assessment, toxicology and pathology services for emerging biopharma; comparable specialty focus and client base to EPL.
  • Labcorp Drug Development: Full-service CRO (formerly Covance) providing preclinical safety, pathology and bioanalytical services; overlaps EPL on toxicologic pathology and SEND data services within an integrated early-development offering.
  • Absorption Systems: Preclinical CRO offering toxicology, pathology and ADME services to pharma and biotech; competes with EPL on toxicologic pathology and SEND-enabled safety packages.
  • Wuxi AppTec: Global preclinical and clinical CRO with extensive toxicologic pathology capacity; direct competitor for international pharma sponsors and a natural alternative to EPL's US-China peer review pathway.

Emerging players

  • ToxStrategies: Scientific consulting firm with capabilities in toxicologic pathology, risk assessment and regulatory strategy; partial overlap with EPL's consulting and pathology peer review offerings.

Broad incumbents

  • Eurofins Discovery: Broader discovery and preclinical services platform including safety assessment and pathology; overlaps with EPL on toxicologic pathology within a much wider CRO and testing portfolio.

Regional players

  • WestChina-Frontier PharmaTech (WCFP): China-based GLP CRO providing safety and efficacy evaluations; EPL's alliance partner and a regional peer for pathology peer review services tied to FDA-bound China studies.

Others

  • PDS Life Sciences: Provider of preclinical software including the Ascentos and TranSEND SEND platforms that EPL has validated; adjacent technology enabler rather than direct pathology services competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Experimental Pathology Laboratorie social profiles

Digital presence

Experimental Pathology Laboratorie financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Experimental Pathology Laboratorie leadership team

Management profile

Number of profiles

Profiles10 records

Experimental Pathology Laboratorie subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Experimental Pathology Laboratorie funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Experimental Pathology Laboratorie M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Experimental Pathology Laboratorie

What does Experimental Pathology Laboratorie do?

Experimental Pathology Laboratories, Inc. (EPL) provides preclinical histopathology and toxicologic pathology services on a project basis to pharmaceutical, biotechnology, and chemical companies as well as government agencies and academia. Services span histology (H&E, immunohistochemistry, specialty stains, necropsy), pathology evaluation (carcinogenicity, peer review, Pathology Working Groups, aquatic/avian pathology), digital whole slide imaging and stereology, transmission electron microscopy, SEND-compliant data services, and expert scientific/regulatory consulting.

Is Experimental Pathology Laboratorie a public or private company?

Experimental Pathology Laboratorie is a private company. It is classified as management employee owned and is currently operating.

When was Experimental Pathology Laboratorie founded?

Experimental Pathology Laboratorie was founded in 1971. It employs 101 to 250 people.

Where is Experimental Pathology Laboratorie based?

Experimental Pathology Laboratorie is headquartered in Sterling, United States, in the North America region.

How does Experimental Pathology Laboratorie make money?

One revenue line is on record: professional Pathology Services.

Who are Experimental Pathology Laboratorie's main competitors?

Direct peers on record are Charles River Laboratories, Inotiv, Seventh Wave Laboratories, Labcorp Drug Development, Absorption Systems and Wuxi AppTec. ToxStrategies is listed as an emerging player. Eurofins Discovery is listed as a broad incumbent. WestChina-Frontier PharmaTech (WCFP) is listed as a regional player. PDS Life Sciences is listed as an others.

Does Experimental Pathology Laboratorie have an API?

No public API is recorded for Experimental Pathology Laboratorie.

What industry is Experimental Pathology Laboratorie in?

Experimental Pathology Laboratorie's product category is Preclinical Pathology Services. Its primary akta.pro industry code is HLAGAFAI, Pathology & Histopathology Services, with a secondary code of HLAGAEAC, Anatomic Pathology & Histopathology (Trial Support). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialFlashpath Announces Commercial Agreement With Experimental Pathology Laboratories For Flashae PlatformFlashPath announced a commercial agreement with Experimental Pathology Laboratories and its Aclairo subsidiary, granting them access to FlashAE, its platform for exploring publicly available drug safety evidence. The agreement integrates preclinical, regulatory, clinical, and post-market safety data into a unified research environment. FlashPath aims to make accumulated safety knowledge more accessible to researchers.EIN PresswireFlashPath Announces Commercial Agreement with Experimental Pathology Laboratories for FlashAE PlatformFlashPath announced that Experimental Pathology Laboratories and its Aclairo subsidiary licensed access to FlashAE, its platform for interpreting publicly available drug safety evidence. The agreement brings integrated preclinical, clinical, and regulatory safety evidence to EPL's toxicologic pathology teams. FlashPath aims to make accumulated safety data more accessible for predictive toxicology.EIN PresswireFlashPath Announces Commercial Agreement with Experimental Pathology Laboratories for FlashAE PlatformFlashPath announced that Experimental Pathology Laboratories and its Aclairo subsidiary licensed access to FlashAE, its platform for interpreting publicly available drug safety evidence. The agreement brings integrated preclinical, clinical, and regulatory safety evidence to EPL's toxicologic pathology teams. FlashPath aims to make accumulated safety data more accessible for researchers.